Protective effect of palmitoylethanolamide in a rat model of cystitis
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Female rats given cyclophosphamide to induce cystitis
- Dose used in the study
- Ultramicronised PEA, given exogenously; exact dose not detailed in the abstract, tested with and without a CB1 antagonist (rimonabant) or a PPAR-alpha antagonist (GW6471)
- Duration
- Not stated in the abstract
- What was measured
- Pain behaviour, voiding frequency, bladder tissue damage, myeloperoxidase activity, bladder weight, bladder PEA and endocannabinoid levels, and CB1, CB2 and PPAR-alpha receptor expression
What the authors reported
Cyclophosphamide raised bladder PEA levels, increased CB1 receptor expression and lowered PPAR-alpha expression. Ultramicronised PEA reduced pain behaviour, voiding frequency and bladder tissue damage. Both rimonabant and GW6471 reduced PEA's protective effect on tissue damage, and GW6471 further reduced voiding frequency in PEA-treated rats.
Limits of this study
A rat model of cyclophosphamide-induced cystitis; it cannot show effect in people with bladder inflammation. Dose is not fully detailed in the abstract. Funding and conflicts not stated in the abstract.
Source
PubMed 25463999 · doi:10.1016/j.juro.2014.11.083
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.